AstraZeneca's Trastuzumab deruxtecan has been approved in India for the treatment of adult patients with unresectable or metastatic HER2-Low breast cancer post-chemotherapy, as well as for individuals with HER2-positive gastric or gastroesophageal cancer following a trastuzumab-based regimen.